Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.69 |
| ▸ | TBXAS1 | P24557 | 15/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | FDPS | P14324 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL9850785 | 0.98 | EGLN3 (0.67) | EGLN3TBXAS1ALDH1A1FDPS | |
| Hydrochloric Acid SCHEMBL2674174 | 0.98 | EGLN3 (0.67) | EGLN3TBXAS1ALDH1A1FDPS | |
| Water SCHEMBL7439834 | 0.98 | EGLN3 (0.67) | EGLN3TBXAS1ALDH1A1FDPS | |
| SCHEMBL4395522 | 0.90 | TBXAS1 (0.64) | EGLN3TBXAS1 | |
| SCHEMBL5805139 | 0.89 | TBXAS1 (0.72) | EGLN3TBXAS1 | |
| SCHEMBL11011547 | 0.87 | TBXAS1 (0.75) | EGLN3TBXAS1 | |
| SCHEMBL29127257 | 0.82 | EGLN3 (0.53) | EGLN3TBXAS1ALDH1A1FDPS | |
| SCHEMBL6427519 | 0.82 | EGLN3 (0.61) | EGLN3TBXAS1ALDH1A1FDPS | |
| SCHEMBL2001103 | 0.82 | EGLN3 (1.00) | EGLN3TBXAS1ALDH1A1 | |
| SCHEMBL14532409 | 0.81 | L3MBTL1 (0.55) | EGLN3TBXAS1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 353 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120079446-A | Manganese-based MOF organic-inorganic hybrid catalyst and preparation method thereof | 上海慷道新材料科技有限公司 | 2025-06-03 | — | — | CN | claimed |
| US-9657014-B2 | Substituted 1,6-naphthyridines | HOFFMANN-LA ROCHE INC. (US) | 2017-05-23 | — | — | US | claimed |
| EP-2763990-B1 | PYRROLOPYRAZINE KINASE INHIBITORS | HOFFMANN LA ROCHE (CH) | 2017-02-22 | — | — | EP | claimed |
| EP-2922540-A1 | SUBSTITUTED 1,6-NAPHTHYRIDINES | F. Hoffmann-La Roche AG (CH) | 2015-09-30 | — | — | EP | claimed |
| US-20150252044-A1 | SUBSTITUTED 1,6-NAPHTHYRIDINES | HOFFMANN-LA ROCHE INC. (US) | 2015-09-10 | — | — | US | claimed |
| EP-1904439-B1 | SPHINGOSINE KINASE INHIBITORS | APOGEE BIOTHECHNOLOGY CORP (US) | 2014-11-26 | — | — | EP | claimed |
| WO-2014079787-A1 | SUBSTITUTED 1,6-NAPHTHYRIDINES | F. HOFFMANN-LA ROCHE AG (CH) | 2014-05-30 | — | — | WO | claimed |
| US-8557796-B2 | Substituted 1-oxa-2,8-diaza-spiro [4,5] dec-2-ene derivatives and related treatment methods | GRUENENTHAL GMBH (DE) | 2013-10-15 | — | — | US | claimed |
| US-8557800-B2 | Sphingosine kinase inhibitors | APOGEE BIOTECHNOLOGY CORPORATION (US) | 2013-10-15 | — | — | US | claimed |
| EP-1971600-B1 | ISOXAZOLE DERIVATIVES AND USE THEREOF | SK BIOPHARMACEUTICALS CO LTD (KR) | 2013-08-21 | — | — | EP | claimed |
| US-20030004172-A1 | Fused pyrimidinone matrix metalloproteinase inhibitors | HARTER WILLIAM GLEN (US) | 2003-01-02 | — | — | US | claimed |
| WO-2002098424-A1 | NOVEL ANTI-INFECTIVES | SMITHKLINE BEECHAM CORPORATION (US) | 2002-12-12 | — | — | WO | claimed |
| WO-2002066446-A1 | HETEROCYCLIC SUBSTITUTED CARBONYL DERIVATIVES AND THEIR USE AS DOPAMINE D3 RECEPTOR LIGANDS | AVENTIS PHARMACEUTICALS INC. (US) | 2002-08-29 | — | — | WO | claimed |
| EP-0892789-B1 | IRREVERSIBLE INHIBITORS OF TYROSINE KINASES | WARNER LAMBERT CO (US) | 2002-02-27 | — | — | EP | claimed |
| WO-2001007409-A1 | CARBAZOLE DERIVATIVES AND THEIR USE AS NEUROPEPTIDE Y5 RECEPTOR LIGANDS | ASTRAZENECA UK LIMITED (GB) | 2001-02-01 | — | — | WO | claimed |
| EP-0892789-A1 | IRREVERSIBLE INHIBITORS OF TYROSINE KINASES | WARNER-LAMBERT COMPANY (US) | 1999-01-27 | — | — | EP | claimed |
| WO-1997038983-A1 | IRREVERSIBLE INHIBITORS OF TYROSINE KINASES | WARNER-LAMBERT COMPANY (US) | 1997-10-23 | — | — | WO | claimed |
| EP-0416740-A2 | Novel compounds with renin-inhibiting activity | Beecham Group p.l.c. (GB) | 1991-03-13 | — | — | EP | claimed |
| EP-0411751-A1 | Renin inhibitory peptides | Beecham Group p.l.c. (GB) | 1991-02-06 | — | — | EP | claimed |
| EP-0375451-A2 | Compounds having a renin-inhibiting activity | BEECHAM GROUP PLC (GB) | 1990-06-27 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030004172-A1 | Fused pyrimidinone matrix metalloproteinase inhibitors | MMP13, MMP3, MMP25 | EGLN3 368/4885TBXAS1 2016/4885ALDH1A1 812/4885 |
| US-20150252044-A1 | SUBSTITUTED 1,6-NAPHTHYRIDINES | CBR3, CBR1, NR2C2 | EGLN3 637/4885TBXAS1 1741/4885ALDH1A1 1072/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.